3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
60
Burkitt Lymphoma
10
Recurrence
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Immunoglobulin Light-chain Amyloidosis
2
Down Syndrome
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Plasmacytoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Interventions
Magnetic Resonance Spectroscopy
28
enzalutamide
23
Specimen Handling
20
apalutamide
17
Androgen Antagonists
14
Radiosurgery
13
Radiotherapy
12
Prednisone
12
Docetaxel
12
Abiraterone Acetate
12
abiraterone
10
Biopsy
10
Radiation
8
niraparib
6
luprolide acetate gel depot
6
darolutamide
6
Pluvicto
6
Leuprolide
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
relugolix
5
gallium 68 PSMA-11
5
cabazitaxel
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Nivolumab
5
Gonadotropin-Releasing Hormone
5
bicalutamide
4
Triptorelin Pamoate
4
Surveys and Questionnaires
4
Radiotherapy, Intensity-Modulated
4
Glutamate Carboxypeptidase II
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Dexamethasone
×
30 days
×
Clear all
NCT06136650
2026-05-27
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled